(68 days)
Not Found
Not Found
No
The description details a simple immunochromatographic assay, which is a chemical test, with no mention of AI or ML technology.
No
This device is a diagnostic test kit for detecting opiates in urine, not a device used for treating a medical condition.
Yes
Explanation: The device is intended for the "rapid, qualitative detection of opiates and its metabolites," which is a form of diagnostic testing to identify the presence of specific substances in the body.
No
The device description clearly states it is an "immunochromatographic assay," which is a physical test kit, not software.
Yes, based on the provided information, the dBest Opiates Test Kit is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states it's for the "rapid, qualitative detection of opiates and its metabolites... in urine". This involves testing a biological sample (urine) outside of the body to gain information about a person's health status (presence of opiates).
- Device Description: The description confirms it's an "immunochromatographic assay" which is a common type of test used for in vitro diagnostics.
- Professional and Laboratory Use: The intended user and care setting being "professional and laboratory use only" is consistent with the use of IVD devices.
These characteristics align with the definition of an In Vitro Diagnostic device, which is used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes.
N/A
Intended Use / Indications for Use
dBest Opiates Test Kit is a simple one step immunochromatographic assay for rapid, qualitative detection of opiates and its metabolites such as codeine and heroin in urine with cutoff of 300 ng/ml. The dBest Opiates Test Kits are for professional and laboratory use only.
Product codes
DJG
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
professional and laboratory use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.3650 Opiate test system.
(a)
Identification. An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy.(b)
Classification. Class II (special controls). An opiate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
Image /page/0/Picture/2 description: The image shows a logo on the left and the date "NOV 1 8 199" on the right. The logo is a circular seal with text around the perimeter and a stylized image in the center. The date is printed in a bold, sans-serif font.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
K. C. Yee, Ph.D., M.D. President AmeriTek, Inc. Diagnostic Division 7030 35th Avenue N.E. Seattle, Washington 98115
Re : K983190 Trade Name: dBest Opiates Test Kit Requlatory Class: II Product Code: DJG Dated: September 10, 1998 September 11, 1998 Received:
Dear Dr. Yee:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Requlation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in requlatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
1
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbrandinq by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Page of
510 (K) Number (if known): K 983190
Device Name: dBest Opiates Test Kits
Indications For Use:
dBest Opiates Test Kit is a simple one step immunochromatographic assay for rapid, qualitative detection of opiates and its metabolites such as codeine and heroin in urine with cutoff of 300 ng/ml. The dBest Opiates Test Kits are for professional and laboratory use only.
(Division
Division of Clinical Laboratory Services
510(k) Number K983190
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PATE IF NEEDEN)
Prescription Use
OR
Over-The -Counter Use (Optional Format 1-2-96)
. . . . . .